O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). (2nd July 2019) - Miksad, R; Cicin, I; Chen, Y; Klumpen, H; Kim, S; Lin, Z; Youkstetter, J; Sen, S; Cheng, A; Meyer, T; Kelley, R; Abou-Alfa, G